计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C127191-10mg |
10mg |
现货 ![]() |
| |
| C127191-25mg |
25mg |
现货 ![]() |
| |
| C127191-50mg |
50mg |
现货 ![]() |
| |
| C127191-100mg |
100mg |
现货 ![]() |
| |
| C127191-250mg |
250mg |
期货 ![]() |
|
| 英文别名 | 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide | AS-16955 | FT-0665231 | UNII-1A7Y9MP123 | BDBM50307768 | GTPL8894 | 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide | SDCCGSBI-0050427.P003 | (+/-) |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | CUDC-101 |
| 生化机理 | CUDC-101 可抑制厄洛替尼耐药的表皮生长因子受体突变体 T790M,但其作用并不完全,抑制后的 Amax 值约为酶活性峰值的 60%。CUDC-101 可增加组蛋白 H3 和 H4 的乙酰化,以及 HDAC 非组蛋白底物(如 p53 和 α-tubulin)的乙酰化。CUDC-101 还能抑制肿瘤细胞中 HER3 的表达、Met 扩增和 AKT 的重新激活。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 组蛋白去乙酰化酶抑制剂 |
| 产品介绍 |
CUDC-101是HDAC,EGFR和HER2抑制剂,IC50分别为4.4,2.4和15.7 nM。A potent inhibitor of HDACs and receptor tyrosine kinases CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively. |
| 纯度 | ≥98% |
| ALogP | 4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504769807 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide |
| INCHI | 1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27) |
| InChi Key | PLIVFNIUGLLCEK-UHFFFAOYSA-N |
| Smiles | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
| Isomeric SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
| 分子量 | 434.49 |
| Reaxy-Rn | 13122626 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=13122626&ln= |
| 溶解性 | DMSO ≥40mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
|---|---|
| 分子量 | 434.500 g/mol |
| XLogP3 | 4.000 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 12 |
| 精确质量Exact Mass | 434.195 Da |
| 单同位素质量Monoisotopic Mass | 434.195 Da |
| 拓扑极表面积Topological Polar Surface Area | 106.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 624.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.. J Med Chem, 53 (5): (2000-9). [PMID:20143778] |
| 2. Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A et al.. (2014) Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.. Clin Cancer Res, 20 (19): (5032-40). [PMID:25107918] |
| 3. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R et al.. (2015) A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.. Clin Cancer Res, 21 (7): (1566-73). [PMID:25573383] |
| 4. Jinzhao Liu, Meicen Wu, Qingyang Lyu, Chang Yang, Ni Fan, Kang Chen, Weiping Wang. (2025) IR783-Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation. Advanced Science, (2415684). [PMID:40150864] [10.1002/advs.202415684] |